181 related articles for article (PubMed ID: 33755348)
1. Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog.
Park SM; Kim KB; Song WJ; Youn HY
Vet Med Sci; 2021 Jul; 7(4):1150-1153. PubMed ID: 33755348
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
[TBL] [Abstract][Full Text] [Related]
3. Old or new? A comparison of mitotane and trilostane for the management of hyperadrenocorticism.
Griffies JD
Compend Contin Educ Vet; 2013 May; 35(5):E3. PubMed ID: 23677783
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism.
Barker EN; Campbell S; Tebb AJ; Neiger R; Herrtage ME; Reid SW; Ramsey IK
J Vet Intern Med; 2005; 19(6):810-5. PubMed ID: 16355673
[TBL] [Abstract][Full Text] [Related]
5. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane.
Reine NJ
Clin Tech Small Anim Pract; 2007 Feb; 22(1):18-25. PubMed ID: 17542193
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment.
Arenas C; Melián C; Pérez-Alenza MD
J Vet Intern Med; 2014; 28(2):473-80. PubMed ID: 24495125
[TBL] [Abstract][Full Text] [Related]
7. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
Helm JR; McLauchlan G; Boden LA; Frowde PE; Collings AJ; Tebb AJ; Elwood CM; Herrtage ME; Parkin TD; Ramsey IK
J Vet Intern Med; 2011; 25(2):251-60. PubMed ID: 21352377
[TBL] [Abstract][Full Text] [Related]
8. A case of adrenal gland dependent hyperadrenocorticism with mitotane therapy in a Yorkshire terrier dog.
Lee YM; Kang BT; Jung DI; Park C; Kim HJ; Kim JW; Lim CY; Park EH; Park HM
J Vet Sci; 2005 Dec; 6(4):363-6. PubMed ID: 16294004
[TBL] [Abstract][Full Text] [Related]
9. Update on the use of trilostane in dogs.
Lemetayer J; Blois S
Can Vet J; 2018 Apr; 59(4):397-407. PubMed ID: 29606727
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
11. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
[TBL] [Abstract][Full Text] [Related]
12. Trilostane treatment of a dog with functional adrenocortical neoplasia.
Eastwood JM; Elwood CM; Hurley KJ
J Small Anim Pract; 2003 Mar; 44(3):126-31. PubMed ID: 12653328
[TBL] [Abstract][Full Text] [Related]
13. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs.
Angles JM; Feldman EC; Nelson RW; Feldman MS
J Am Vet Med Assoc; 1997 Oct; 211(8):1002-4. PubMed ID: 9343543
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism.
Cook AK; Bond KG
J Am Vet Med Assoc; 2010 Oct; 237(7):801-5. PubMed ID: 20919845
[TBL] [Abstract][Full Text] [Related]
15. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.
Macfarlane L; Parkin T; Ramsey I
Vet Rec; 2016 Dec; 179(23):597. PubMed ID: 27803375
[TBL] [Abstract][Full Text] [Related]
16. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
Reid LE; Behrend EN; Martin LG; Kemppainen RJ; Ward CR; Lurye JC; Donovan TC; Lee HP
J Vet Intern Med; 2014; 28(2):443-50. PubMed ID: 24400747
[TBL] [Abstract][Full Text] [Related]
17. Haptoglobin concentrations in dogs undergoing trilostane treatment for hyperadrenocorticism.
McGrotty YL; Arteaga A; Knottenbelt CM; Ramsey IK; Eckersall PD
Vet Clin Pathol; 2005 Sep; 34(3):255-8. PubMed ID: 16134074
[TBL] [Abstract][Full Text] [Related]
18. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
Mantis P; Lamb CR; Witt AL; Neiger R
Vet Radiol Ultrasound; 2003; 44(6):682-5. PubMed ID: 14703251
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Nelson RW; Feldman MS; Farver TB
J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
[TBL] [Abstract][Full Text] [Related]
20. Mitotane (o,p'-DDD) resistance in a dog with pituitary-dependent hyperadrenocorticism and phaeochromocytoma.
Bennett PF; Norman EJ
Aust Vet J; 1998 Feb; 76(2):101-3. PubMed ID: 9578778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
